Table 1

Characteristics of patients from T cell-inflamed, intermediate, and non-T cell-inflamed tumor groups in the discovery cohort (TARGET)

CharacteristicT cell-inflamed
N=57, no (%)
Intermediate
N=47, no (%)
Non-T cell-inflamed
N=45, no (%)
P-value
Age0.088
 <18 months6 (11)11 (23)12 (27)
 ≥18 months51 (89)36 (77)33 (73)
Sex0.2
 Female26 (46)22 (47)14 (31)
 Male31 (54)25 (53)31 (69)
Race0.7
 Asian1 (2)0 (0)0 (0)
 Black or African American8 (15)9 (20)9 (24)
 Native Hawaiian or other
 Pacific Islander
0 (0)1 (2)1 (3)
 White43 (83)36 (78)27 (73)
 Unknown518
Ethnicity0.5
 Hispanic or Latino3 (6)5 (12)5 (12)
 Not Hispanic or Latino49 (94)38 (88)37 (88)
 Unknown543
INSS stage0.008**
 Stage 33 (5)2 (4)0 (0)
 Stage 452 (91)37 (79)34 (76)
 Stage 4S2 (4)8 (17)11 (24)
MYCN status<0.001***
 Amplified3 (5)11 (23)17 (38)
 Not amplified53 (95)36 (77)28 (62)
 Unknown100
Histology0.078
 Favorable6 (11)12 (29)10 (23)
 Unfavorable48 (89)29 (71)33 (77)
 Unknown362
Ploidy0.4
 Diploid28 (50)17 (36)20 (44)
 Hyperdiploid28 (50)30 (64)25 (56)
 Unknown100
COG risk group0.069
 High risk53 (92)37 (79)33 (73)
 Intermediate risk2 (4)6 (13)5 (11)
 Low risk2 (4)4 (8)7 (16)
  • P values were calculated using one-way analysis of variance, χ2 test, Fisher’s exact test.

  • *p<0.05, **p<0.01, ***p<0.001.

  • COG, Children’s Oncology Group; INSS, International Neuroblastoma Staging System; TARGET, Therapeutically Applicable Research to Generate Effective Treatments.